Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in KRAS-mutated non-small cell lung cancer with STK11, KEAP1, or TP53 comutations: subgroup results from the phase III IMpower150 trial

BACKGROUND: The efficacy of atezolizumab (A) and/or bevacizumab (B) with carboplatin/paclitaxel (CP) chemotherapy was explored in the phase III, randomized IMpower150 study in patients with non-squamous non-small cell lung cancer (NSCLC) according to KRAS mutations (mKRAS) and co-occurring STK11, KE...

Descripción completa

Detalles Bibliográficos
Autores principales: West, Howard Jack, McCleland, Mark, Cappuzzo, Federico, Reck, Martin, Mok, Tony SK, Jotte, Robert M, Nishio, Makoto, Kim, Eugene, Morris, Stefanie, Zou, Wei, Shames, David, Das Thakur, Meghna, Shankar, Geetha, Socinski, Mark A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Immunotherapy Biomarkers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8862451/
https://www.ncbi.nlm.nih.gov/pubmed/35190375
http://dx.doi.org/10.1136/jitc-2021-003027

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8862451/
https://www.ncbi.nlm.nih.gov/pubmed/35190375
http://dx.doi.org/10.1136/jitc-2021-003027

Ejemplares similares